The human induced pluripotent stem cell (iPSC) research landscape is rapidly evolving. We recently discussed the current trend in stem cell research to streamline the production of induced pluripotent stem cells (iPSC) from peripheral blood mononuclear cells (PBMCs). Recent exciting studies have indicated that harnessing iPSCs self-renewal ability to manufacture cell therapies is now becoming a reality. Just 4 years ago, the pharmaceutical company Takeda and The Center for iPS Cell Research and Application (CiRA) at Kyoto University entered a 10-year joint research collaboration. A few weeks ago, it was announced that Takeda has advanced the first product from its collaboration with CiRA - a highly scalable off-the-shelf CAR-T cell therapy to treat cancer - into pre-clinical development.[1] Here, we briefly discuss the iCART science behind the Takeda study and its potential implications for an “off-the-shelf” CAR-T cell therapy.
Researchers at the University of Melbourne are studying how to boost the body’s immune system to help fight off certain cancers through a healthy microbiome.
The microbiome, the collective group or community of microorganisms that have a tight connection and relationship with the rest of our bodies, is essential for our healthy existence. The most studied microbiome is that of the intestines, and it is now known to play a crucial role in more than digestion. There is a critical balance between types of microbes (bacterial, fungi, viruses) that influences the body’s biochemistry, such as cholesterol levels, blood glucose, and even brain function.
Researchers at Johns Hopkins University and IBM Thomas J Watson Research Center discovered unique autoimmune cells in type 1 diabetes.
Over 30 million people living in the United States are affected by diabetes, and 5% of those have type 1 diabetes, an autoimmune disorder whereby the insulin-producing cells of the pancreas are destroyed by the body’s own immune system. This leads to a lack of sufficient insulin needed to assist the entry of glucose into cells, causing hyperglycemia. The mechanism of this aspect is mainly unknown. However, it is held that insulin is the target of the autoimmune attack that leads to type 1 diabetes.
A new treatment has been approved by the FDA to treat breast cancer that combines chemotherapy with immunotherapy.
The war against cancer is ongoing and consists of both winning and losing battles. There are several cancers that have been successfully treated with immunotherapy. However, one type of cancer has been a challenge for the application of immunotherapy is breast cancer. There are various subtypes of breast cancer, and each requires a different treatment approach due to the distinct biology associated with these cancer types and the specific mechanisms involved in breast tumor development.
A new study shows that NK cells may be able to form adaptive memory and demonstrate specific antigen memory.
Innate immunity has long been considered the nonspecific first line of defense against an invading microorganism, while adaptive (or acquired) immunity is an antigen-specific immune response characterized by a memory that allows protection against a repeat exposure. Examples of cells of the innate immune response include natural killer (NK) cells, macrophages, neutrophils, and mast cells. T and B lymphocytes are cells of the adaptive immune system.